Applications

1350 – Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New MBS item.

Service or technology in this application

This service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion.

Type: Co-dependent technology

Medical condition this application addresses

RVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.

Application documents

Optical Coherence Tomography (OCT) – Assessment of investigative medical services for monitoring

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: -